Chargement en cours...
Targeting energy metabolism of cancer cells: Combined administration of NCL-240 and 2-DG
Cancer cells increase their metabolism to produce the energy and biomolecules necessary for growth and proliferation. Thus, energy metabolism pathways may serve as targets for anti-cancer therapy. NCL-240 is a second generation anti-cancer drug belonging to the PITenins class of PI3K-Akt inhibitors....
Enregistré dans:
| Publié dans: | Int J Pharm |
|---|---|
| Auteurs principaux: | , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5628159/ https://ncbi.nlm.nih.gov/pubmed/28844900 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ijpharm.2017.08.095 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|